Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002170 · ClinicalTrials.gov registry record · Phase 2
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002170: Completed Phase 2 study, sponsored by Agouron Pharmaceuticals.
NCT00002170 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002170, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
Interventions
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002170 record still lists
NCT00002170 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002170 about?
NCT00002170 is a clinical study titled "A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)". The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
What is the current status of trial NCT00002170?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002170?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002170?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.